Idexx stock fell Monday despite beating fourth-quarter expectations and issuing strong guidance for 2026.

IDEXX beat Q4 expectations, but weak vet visit trends and softer guidance pressured shares. Click here to find out why IDXX ...

IDEXX Laboratories (NASDAQ:IDXX) reported double-digit fourth-quarter growth and laid out its initial 2026 outlook, ...

IDEXX Laboratories, Inc. (NASDAQ:IDXX) Q4 2025 Earnings Call Transcript February 2, 2026 IDEXX Laboratories, Inc. beats ...

IDXX tops Q4 EPS and revenue estimates as margins expand. However, shares dip during the pre-market trading, while 2026 ...

IDEXX Laboratories Inc. (NASDAQ: IDXX) reported better-than-expected fourth-quarter financial results and issued a fiscal 2026 forecast on Monday.

The Q4 earnings report for IDEXX Laboratories (NASDAQ: IDXX) was released on Monday, February 2, 2026 at 06:30 AM. Here's ...

Idexx delivered revenue and EPS growth of 6% and 13% in Q4, but its guidance appears to have caught the market's attention. Looking ahead to 2025, management expects the company to grow sales by 4% to ...

Detailed price information for Idexx Laboratories (IDXX-Q) from The Globe and Mail including charting and trades.

WESTBROOK, Maine - IDEXX Laboratories (NASDAQ:IDXX) reported strong fourth quarter results on Monday, with revenue climbing 14% to $1.09 billion, exceeding analyst expectations of $1.07 billion, ...

Idexx Laboratories has steadily increased its scale and reach in the veterinary diagnostic lab business to dig a narrow moat. It is well-positioned to benefit from two key trends. First, pet ownership ...